1. Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer
- Author
-
Prieto-Potin, I. (Iván), Montagut, C. (Clara), Bellosillo, B. (Beatriz), Evans, M. (Matthew), Smith, M. (Matthew), Melchior, L. (Linea), Reiltin, W. (Werner), Bennett, M. (Michael), Pennati, V. (Veronica), Castiglione, F. (Francesca), Bürrig, K.-F. (Karl-Friedrich), Cooper, U. (Ulrike), Dockhorn-Dworniczak, B. (Barbara), Rossenbach, C. (Christiana), Luna-Aguirre, C.M. (Claudia M.), Barrera-Saldaña, H.A. (Hugo A.), MacHado, J.C., Costa, J.L. (José), Yacobi, R. (Rinat), Tabibian-Keissar, H. (Hilla), Buglioni, S. (Simonetta), Ronchetti, L. (Livia), Douglas-Berger, L. (Lotte), Dubbink, H.J. (Erik Jan), Alorini, M. (Mohammed), Sabourin, J.C., Rojo, F. (Federico), Prieto-Potin, I. (Iván), Montagut, C. (Clara), Bellosillo, B. (Beatriz), Evans, M. (Matthew), Smith, M. (Matthew), Melchior, L. (Linea), Reiltin, W. (Werner), Bennett, M. (Michael), Pennati, V. (Veronica), Castiglione, F. (Francesca), Bürrig, K.-F. (Karl-Friedrich), Cooper, U. (Ulrike), Dockhorn-Dworniczak, B. (Barbara), Rossenbach, C. (Christiana), Luna-Aguirre, C.M. (Claudia M.), Barrera-Saldaña, H.A. (Hugo A.), MacHado, J.C., Costa, J.L. (José), Yacobi, R. (Rinat), Tabibian-Keissar, H. (Hilla), Buglioni, S. (Simonetta), Ronchetti, L. (Livia), Douglas-Berger, L. (Lotte), Dubbink, H.J. (Erik Jan), Alorini, M. (Mohammed), Sabourin, J.C., and Rojo, F. (Federico)
- Abstract
Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15 of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround time) sample-to-result solution, enabling the detection of clinically relevant mutations in NRAS (18 mutations) and BRAF (5 mutations). A multicenter study was conducted in 14 centers using the Idylla NRAS-BRAF Mutation Test to assess the NRAS and BRAF mutational status of 418 formalin-fixed, paraffin-embedded tissue samples from CRC patients. Results were compared with those obtained earlier by routine reference methods, including next-generation sequencing, pyrosequencing, mass spectrometry–based assays, PCR-based assays, and Sanger sequencing. In case of discordance, additional tests were performed by digital droplet PCR. Overall, after testing confirmation and excluding invalids/errors by design, concordances between the Idylla NRAS-BRAF Mutation Test and the reference test results were found in almost perfect agreement. In conclusion, the Idylla NRAS-BRAF Mutation Test enables the routine detection of all NRAS and BRAF mutations deemed clinically relevant according to the latest clinical guidelines, without necessitating molecular expertise or infrastructure.
- Published
- 2018
- Full Text
- View/download PDF